Health and Healthcare
Eleven Biotherapeutics Soars on Investigational Milestone
Published:
Last Updated:
Shares of Eleven Biotherapeutics Inc. (NASDAQ: EBIO) saw a handy gain early on Friday. The company announced that its Investigational New Drug (IND) application for EBI-031 has become effective. As a result of the achievement of this milestone, Eleven is entitled to receive a $22.5 million payment from Roche pursuant to the terms of its license agreement with Roche.
On June 13, the company announced that it had entered into an exclusive license agreement with Roche for the further development and commercialization of EBI-031 and all other IL-6 antagonist antibody technology owned by Eleven.
Under the terms of this agreement, Eleven could receive up to $262.5 million upon the achievement of certain regulatory, development and commercialization milestones, including this $22.5 million payment upon the effectiveness of the IND for EBI-031.
Additionally, Eleven could be entitled to receive royalties for net sales of potential future products containing EBI-031 or any other potential future products containing other Eleven IL-6 compounds. Effectiveness of the license agreement, including Roche’s obligation to make the $22.5 million milestone payment, is subject to approval of the license by holders of at least a majority of the outstanding shares of Eleven’s common stock.
Abbie Celniker, Ph.D., president and CEO of Eleven Bio, commented:
We look forward to Roche advancing EBI-031 into the clinic to explore its potential use for ocular diseases, such as diabetic macular edema, in an effort to bring this potential treatment to patients.
Excluding this move, Eleven Bio has underperformed the broad markets with the stock down 35% year to date. Over the past 52 weeks, the stock is down about 37%.
Shares of Eleven Bio closed Thursday down 3.5% at $1.96, with a consensus analyst price target of $12.00 and a 52-week trading range of $0.25 to $8.00. Following the announcement, the company was up about 43% at $2.80.
Essential Tips for Investing (Sponsored)
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
